Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Primary Myelofibrosis 3Myeloproliferative Disorders 3Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Inhibition, Psychological 1Hodgkin Disease 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1B-cell Malignancies 1B-Cell Malignancies 1

Interventions

Paclitaxel 37Carboplatin 28pembrolizumab 19Surveys and Questionnaires 11temsirolimus 10Radiotherapy 10Cisplatin 10Doxorubicin 9Bevacizumab 9lenvatinib 8Docetaxel 8Nivolumab 7Metformin 7Gemcitabine 7Early Intervention, Educational 7Counseling 7Sirolimus 6Radiation 6Megestrol Acetate 6Indocyanine Green 6olaparib 5Topotecan 5Therapeutics 5Psychiatric Rehabilitation 5Methods 5Letrozole 5Ipilimumab 5Chemotherapy, Adjuvant 5ridaforolimus 4Trastuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Neoplasms × itacitinib × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡